Clinical Study on the Safety and Efficacy of Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy for Adult Relapsed/Refractory Acute Myeloid Leukemia.

NCT06786299 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

NOT_YET_RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Relapsed/Refractory Acute Myeloid Leukemia(AML)

Interventions

BIOLOGICAL: RD-IIT-001
DRUG: CD84-CART

Sponsor

First Affiliated Hospital of Zhejiang University

Collaborators

[object Object]